Braunstein's Hudson Executive Capital LP reported a 5.6% stake in AtriCure, Inc. Hudson Executive in today's filing said it had and may continue to have discussions with AtriCure's management and members of the board to discuss the company's business, strategies and corporate governance. Hudson have found the conversations to date "to be constructive, and may seek to have additional conversations." The discussions have "included, and may continue to include, options for enhancing shareholder value through various strategic alternatives including, but not limited to, optimizing the cash flows associated
with their existing product portfolio, maximizing the value of and prioritizing the capital allocation for various pipeline products, the evaluation of potential strategic partners, and general corporate matters," Hudson stated.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
ATRICURE, INC. 
